“U.S. government plans to rein in drug prices could discourage work in some of Novartis’s most promising areas of research, the Swiss drugmaker warned on Friday, urging Washington to rethink the “unintended” effects of its new rules… Lawmakers’ intention may be to favour sophisticated biologics over seemingly more conventional chemical drugs, but some of the most promising new treatment approaches belong to the latter group, said Victor Bulto, Novartis’s President Innovative Medicines for the U.S. market. “The most concerning piece in that legislation for us is the price setting after nine years for small molecules and 13 years for biologics,” Bulto told Reuters.”
All entries for: Oncology
May 8, 2023
Coherus BioSciences
Negative Outlook
Camarillo, CA
201-500 employees
201-500 employees
Disease Area: Oncology
Drug Type: Biologic
May 5, 2023
AbbVie
Negative Outlook
Chicago, IL
50,001+ employees
50001+ employees
Disease Area: Oncology
Drug Type: Biologic
May 5, 2023
Merck
Negative Outlook
Rahway, NJ
50,001+ employees
50001+ employees
Disease Area: Oncology
Drug Type: Biologic, Small Molecule
May 4, 2023
Beigene
Negative Outlook
Cambridge, MA
5,001-10,000 employees
5001-10000 employees
Disease Area: Oncology
Drug Type: Biologic
April 27, 2023
Eli Lilly & Company
Negative Outlook
Indianapolis, IN
10,001-50,000 employees
10001-50000 employees
Disease Area: Multiple, Oncology
Drug Type: Biologic
April 26, 2023
Alkermes
Negative Outlook
Dublin, Ireland
1,001-5,000 employees
1001-5000 employees
Disease Area: Oncology
Drug Type: Small Molecule
January 20, 2023
Novartis
Negative Outlook
Basel, Switzerland
50,001+ employees
50001+ employees
Disease Area: Multiple, Oncology
Drug Type: Small Molecule
November 9, 2022
Xilio Therapeutics
Negative Outlook
Waltham, MA
51-200 employees
51-200 employees
Note: Xilio described the IRA in a risk section entitled “Current and future legislative efforts may limit the prices for our products, if and when they are licensed for marketing, and that could materially impact our ability to generate revenues”
Disease Area: Oncology
Drug Type: Biologic
November 9, 2022
Context Therapeutics
Negative Outlook
Philadelphia, PA
1-50 employees
1-50 employees
Concern Over Ability to Sell Product: “The passage of the Inflation Reduction Act of 2022 may negatively impact our ability to sell our product candidates, if approved, profitably”
Disease Area: Oncology
Drug Type: Biologic
November 8, 2022
Zymeworks
Negative Outlook
Middletown, DE
201-500 employees
201-500 employees
Concerns over Revenue Generation: “The implementation of cost containment measures, including the prescription drug provisions under the Inflation Reduction Act, as well as other healthcarereforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved”
Disease Area: Multiple, Oncology, Therapeutics
Drug Type: Biologic
